Key result
Seroprevalence of Trypanosoma cruzi cross-reactive antibodies was estimated at 45% in non-exposed French blood donors, showing a progressive acquisition from early childhood without association to other common viral serologies.
Cross-Sectional (n=753)
Yes
A high seroprevalence of cross-reactive antibodies to a T. cruzi antigen was found in non-exposed French individuals, which may cause false-positive results in Chagas screening assays.
Answers are grounded in this paper and cite their sources.
May prompt caution interpreting Chagas serology in non-endemic donors; leaves open assay specificity and cross-reactivity etiology.
Cross-reactive antibodies are characterized by their recognition of antigens that are different from the trigger immunogen. This happens when the similarity between two different antigenic determinants becomes adequate enough to enable a specific binding with such cross-reactive antibodies. In the present manuscript, we report the presence, at an "abnormal" high frequency, of antibodies in blood samples from French human subjects cross-reacting with a synthetic-peptide antigen derived from a Trypanosoma cruzi (T. cruzi) protein sequence. As the vector of T. cruzi is virtually confined to South America, the parasite is unlikely to be the trigger immunogen of the cross-reactive antibodies detected in France. At present, the cross-reactive antibodies are measured by using an in-house ELISA method that employs the T. cruzi -peptide antigen. However, to underline their cross-reactive characteristics, we called these antibodies "Trypanosoma cruzi Cross Reactive Antibodies" or TcCRA. To validate their cross-reactive nature, these antibodies were affinity-purified from plasma of healthy blood donor and were then shown to specifically react with the T. cruzi parasite by immunofluorescence. Seroprevalence of TcCRA was estimated at 45% in serum samples of French blood donors while the same peptide-antigen reacts with about 96% of T. cruzi -infected Brazilian individuals. In addition, we compared the serology of TcCRA to other serologies such as HSV 1/2, EBV, HHV-6, CMV, VZV, adenovirus, parvovirus B19, mumps virus, rubella virus, respiratory syncytial virus, measles and enterovirus. No association was identified to any of the tested viruses. Furthermore, we tested sera from different age groups for TcCRA and found a progressive acquisition starting from early childhood. Our findings show a large seroprevalence of cross-reactive antibodies to a well-defined T. cruzi antigen and suggest they are induced by a widely spread immunogen, acquired from childhood. The etiology of TcCRA and their clinical relevance still need to be investigated.
No takes yet. Share an insight, caveat, or question.
Saba et al. (2013) conducted a cross-sectional in Healthy blood donors and hospital patients (non-exposed to T. cruzi) (n=753). Trypanosoma cruzi synthetic peptide (TCSP) antigen was evaluated on Seroprevalence of Trypanosoma cruzi Cross-Reactive Antibodies (TcCRA) in French blood donors. Seroprevalence of Trypanosoma cruzi cross-reactive antibodies was estimated at 45% in non-exposed French blood donors, showing a progressive acquisition from early childhood without association to other common viral serologies.
Synapse has enriched 10 related papers. Consider them for comparative context: